Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07262619 · ClinicalTrials.gov registry record · Phase 1
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
A Phase 1 study of Endometrial Cancer and Advanced Solid Tumors, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 10
- Study locations
NCT07262619 is a Phase 1 study of Endometrial Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 160 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (69% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT07262619, a Phase 1 study of Endometrial Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 10
- Study locations
Study Summary
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Conditions Studied
Interventions
- DRUG EIK1005
- DRUG pembrolizumab (KEYTRUDA® )
Study Locations (10)
Victoria
- Grampians Health - Ballarat
- Chris O'Brien Lifehouse (Sydney Cancer Centre) - Camperdown
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital - Frankston
- Peninsula and Southeast Oncology (PASO) Medical - Frankston
New South Wales
- GenesisCare North Shore (Oncology) - Saint Leonards
- Calvary Mater Newcastle Hospital - Waratah
New Jersey
- Morristown Medical Center - Morristown
New York
- Memorial Sloan Kettering Cancer Center (MSKCC) - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
Other
- Health New Zealand - Wellington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07262619
The ClinicalTrials.gov registry entry for NCT07262619 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which EIK1005 is the first listed.
NCT07262619 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Victoria, New South Wales, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07262619 about?
NCT07262619 is a clinical study titled "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors". The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
What is the current status of trial NCT07262619?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2026-01-22. Estimated completion is 2029-03.
What conditions does trial NCT07262619 study?
This clinical trial studies the following conditions: Endometrial Cancer, Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H or dMMR Advanced Solid Tumors.
What interventions are being tested in trial NCT07262619?
The interventions under investigation include: EIK1005 (DRUG), pembrolizumab (KEYTRUDA® ) (DRUG).
Who is sponsoring clinical trial NCT07262619?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07262619 being conducted?
This trial has 10 study locations across New Jersey, New York, Texas, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.